Zelira Therapeutics Ltd. · ASX:ZLD
Zelira Therapeutics — Zelda Therapeutics — Shareholder Meeting (November 2017)
24 slides from Zelira Therapeutics's shareholder meeting presentation, Nov 24, 2017
Slide 1: Annual General Meeting Presentation November 2017
For personal use only ANNUAL GENERAL MEETING PRESENTATION NOVEMBER 2017 ZELDA THERAPEUTICS ASX:ZLD www.zeldatherapeutics.com
Slide 2: Disclaimer and Important Notice
Disclaimer and Important Notice For personal use only Disclaimer This presentation has been prepared by Zelda Therapeutics Ltd ACN 103 782 378(“Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Com
Slide 3: Corporate Overview
Corporate ➢ Funds to execute research programme, new Overview For personal use only opportunities and grow clinical pipeline of medicinal cannabis therapies. ➢ A strong pipeline of activities and good news flow Cash at Bank over last 6 months reflected in share price A$7.24M as at movements. 30 Sept
Slide 4: Company Overview
Company For personal use only Overview Access to USA & Chilean patient data Existing patient data demonstrates clinical efficacy of Zelda’s Zelda Therapeutics was proprietary formulations in a range of diseases. founded out of the USA to focus on delivering validated medical cannabis therapies to Ad
Slide 5: Board & Management Team
Board & Management Team For personal use only Harry Karelis Mara Gordon Jason Peterson Dr Stewart Washer Founder & Executive Founder & Founder & Founder & Chairman Director Director Director Harry is a co-founder Mara is the co-founder Jason is a Director, Stewart has 25 years of Jindalee Partners o
Slide 6: Medical Advisory Board
Medical Advisory Board For personal use only Prof. Manuel Guzman Dr Cristina Sanchez Dr Joe Goldstrich Dr Noah Federman Full Professor of Assistant Professor Distinguished clinical Highly respected Biochemistry and at Complutense career in preventive paediatric clinical Molecular Biology at Universi
Slide 7: Cannabis
Cannabis 101 For personal use only ✓ Cannabis contains over 100 different phyto-cannabinoids (including the well-known THC & CBD). ✓ Cannabinoids bind to natural receptors in the body within the endocannabinoid system that are present in the nervous system & throughout the immune system. ✓ Wide rang
Slide 8: Targeted Areas in Large Patient Markets
Targeted Areas in Large Patient Markets For personal use only ✓ Breast – over 1.7m patients in 2012 [Source: World Cancer Research Fund] ✓ Pancreatic – 12th most common cancer globally [Source: Pancreatic Cancer World Research Fund]. Insomnia affects CANCER approx. 35% of adults ✓ Glioblastoma (brai
Slide 9: Pre-clinical Breast Cancer Research
For personal use only Initial results showed THC-rich oil was significantly more potent than pure THC and was as potent as Lapatanib in reducing tumour growth. Zelda’s formulations tested in vitro on three breast cancer lines: ➢ Hormone Receptor Pre-clinical Positive (ER/PR+) ➢ HER2 Positive ➢ Tripl
Slide 10: Pre-clinical Breast Cancer Research
For personal use only Pre-clinical ➢ Potential for cannabinoid-based therapies to be therapeutically beneficial in breast cancer types including hormone receptor positive, HER2+ and Breast Cancer Triple Negative cancer types. Research ➢ Zelda’s THC-rich formulation had greater anti-cancer effect tha
Slide 11: Breast Cancer | Expanded Research
Breast Cancer | Expanded Research For personal use only Cancer Stem Cell-like Cells Encouraging results led to an expansion of Zelda’s current research programme with TUMOUR REGRESSION Complutense University to investigate the CANCER STEM CELL effect of cannabinoids on cancer stem cell- SPECIFIC THE
Slide 12: Clinical Autism Trial in Chile
For personal use only Clinical Autism is a lifelong development disability characterised by impairments in social communication and interactions [Source: Autism Spectrum]. Autism Trial in Chile ➢ Zelda partnered with Chilean non profit organisation Fundacíon Daya - extensive experience in using medi
Slide 13: Autism | Success in Observation Trial
Autism | Success in Observation Trial For personal use only Sponsored observation autism trial in Chile, demonstrated successful results for treating core symptoms of autism with medicinal cannabis extracts that Zelda is planning on taking into clinical trials. Results were presented at the prestigi
Slide 14: Why Chile? Clinical Trial Programme in Chile
For personal use only Chilean legal framework recognises importance of medicinal cannabis, allowing production under strict regulatory controls for treatment of medical conditions. Patients in Chile being treated with medical cannabis Why Chile? through Fundacíon Daya Cost effective location to cond
Slide 15: Clinical Insomnia Trial in Australia
For personal use only ➢ Insomnia affects approximately 35% of adults [Source: GlobalData]. Clinical Current Insomnia treatment ➢ Benzodiazepines are tranquilisers usually prescribed Insomnia for anxiety and insomnia. Trial in Australia ➢ Overdoses from these cause almost 3 times more deaths than her
Slide 16: Strategic Partnerships
Strategic Partnerships For personal use only Strategic partnership with Chilean Access to patient data, formulations non-profit group who have and protocols for company’s current extensive experience in using pre-clinical activities and clinical medicinal cannabis to treat patients activities. diagn
Slide 17: Other Strategic Partnerships
Other Strategic Partnerships For personal use only Strategic partnership with Australian Agreement in place with Chilean Animal Health company developing pharmaceutical manufacturing a range of medicinal cannabis group to provide high quality supply products for animal markets. Zelda of Zelda’s form
Slide 18: Milestones Achieved Since Listing
Milestones Achieved Since Listing For personal use only 3Q Autism | Success in Observation trial (Sept 2017) Chile Research Programme | Expanded team 2017 Results demonstrate cannabis extract more effective than Secured access to team of top scientists in Chile conventional autism medicines. to mana
Slide 19: Comparative Analysis
Comparative Analysis For personal use only GW Pharma - Revenue US$13m FY16 - 45 Phase 2/3 clinical trials Zelda Therapeutics ✓ Existing patient data 2018 ✓ Multiple indications ✓ Multiple formulations In vitro Pre-clinical Clinical validation Approved & Marketed Company Market Capitalisation Focus Z
Slide 20: Commercialisation & Revenue Model
Commercialisation & Revenue Model For personal use only Commercialisation Conduct studies with License or partner with Design key pre-clinical research institutions and leading pharma/biotech and clinical studies specialist clinical research or Distribution Partner organisations (CROs) • Up-front an
Slide 21: Zelda in The Media
For personal use only Zelda in The Media
Slide 22: Activity Pipeline 2018
Activity Pipeline 2018 For personal use only Clinical trials expected to commence ECZEMA in Q3 2018 Clinical trials expected to commence in Q1 2018 with trial data expected SLEEP DISORDER around 6 months later. Clinical trials expected to commence AUTISM in Q1 2018 Research programme expected to PAN
Slide 23: Investment Summary
Investment Summary Zelda Therapeutics offers investors exposure to a world-class team at very attractive valuations and with significant valuation drivers over the next 12-18 months. For personal use only Significant market Acceleration straight to Large target market with opportunity: Medical clini
Slide 24: Contact
@ZeldaTherapeutics For personal use only @ZLDTherapeutics CONTACT Zelda Therapeutics Dr. Stewart Washer Executive Director AUSTRALIA Level 45, 108 St Georges Tce, Perth WA, 6000 USA 575 Highway 1, Bodega Bay, CA, 94923 +61 418 288 212 swasher@zeldatherapeutics.com www.zeldatherapeutics.com
Zelda Therapeutics — Shareholder Meeting (November 2017) on 6ix